Rare recurring balanced XXXX in therapy-related @entity2590 and @entity3052 : report from an international workshop.

@entity1 @entity981 @entity66 @entity0 @entity2590 @entity3052 @entity1893 @entity2008 @entity978
Seventy-seven @entity1 were identified with Rare recurring (excluding 11q23, 21q22, inv(16), and t(15;17)) @entity2008 among 511 @entity1 with treatment-related @entity2590 and @entity3052 accepted from centers in the United States, Europe, and Japan. The abnormality subsets included 3q21q26 (17 @entity1 ), 11p15 (17 @entity1 ), t(9;22)(q34;q11) (10 @entity1 ), 12p13 (9 @entity1 ), t(8;16)(p11;p13) (9 @entity1 ), and an "other" subset, which included t(6;9)(p23;q34) (3 @entity1 ), t(10;11)(p13;q13 approximately q21) (3 @entity1 ), t(1;17)(p36;q21) (2 @entity1 ), t(8;14)(q24;q32) (2 @entity1 ), t(11;19)(q13;q13) (2 @entity1 ), t(1;3)(p36;q21) (2 @entity1 ), and t(3;5)(q21;q31) (1 @entity1 ). Increased karyotypic complexity with additional balanced and unbalanced rearrangements was observed in 70% of cases. Among 54 cases with @entity2008 were observed in 59%. The most frequent @entity66 were @entity0 (24 cases), @entity978 (14 cases), @entity1893 (10 cases), and de novo @entity981 (5 cases). Thirty-seven @entity1 received alkylating agents plus topoisomerase II inhibitors with or without radiation therapy. The presenting diagnosis was t-AML in 47 cases, t-MDS in 23 cases (10 progressed to t-AML), and t- @entity981 in seven cases, five of whom had a t(9;22). The median latency time from initiation of original therapy to therapy-related disease diagnosis was quite long (69 months), and the overall median survival from the date of therapy-related disease diagnosis was very short (7 months). The 1-year survival rate was 34 +/- 7%, with no significant differences among subsets. Comparison with previously reported cases showed increased karyotypic complexity and adult presentation of pediatric-associated @entity2008 .
